Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib + Enzalutamide in AR+ PTEN+ Metastatic Breast Cancer
NCT03207529Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alpelisib in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jun 2019; status: completed.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03207529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207529.